CD274 and neoplasm: At present, PD-1/PD-L1 immune checkpoint inhibitors have been considered for the treatment of tumors due to their significant role in remodeling the tumor microenvironment and releasing PD-1/PD-L1 binding inhibitory effects in various histological tumors.